INPACT: Implementation of Nutritional Support and Physical Activity During Cancer Treatment
Primary Liver Cancer · Liver Metastasis
What this study involves
The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.
- Study type
- Interventional
- Phase
- Not applicable
- Age range
- 18 years - Not specified
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 103 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
The INPACT study investigates whether a structured program combining physical exercise, nutritional support, and breathing exercises can improve physical fitness and recovery in patients undergoing liver surgery for cancer.
Approximately 103 adult patients with primary liver cancer or liver metastases who are scheduled for liver resection will participate. Participants will be randomly assigned to one of two groups. The control group will receive usual care, including general advice on maintaining physical activity and a healthy diet. The intervention group will follow a structured prehabilitation and rehabilitation program consisting of supervised and home-based exercise, nutritional support including protein supplementation, and daily breathing exercises.
The program starts approximately four weeks before surgery and continues after surgery during the rehabilitation period. Both groups will undergo assessments of physical fitness, muscle strength, nutritional status, quality of life, and other health outcomes at several time points before and after surgery.
The primary aim of the study is to determine whether the multimodal prehabilitation program improves patients' functional capacity before surgery. The study will also evaluate physical performance, nutritional status, quality of life, postoperative recovery and complications, safety, and adherence to the program.
Read the full description
INPACT (Implementation of Nutritional Support and Physical Activity during Cancer Treatment) is a prospective randomized controlled trial investigating the role of multimodal prehabilitation in patients undergoing oncological liver resection for primary liver cancer or liver metastases.
Patients undergoing liver surgery frequently present with impaired physical fitness, nutritional deficits, reduced physiological reserve, and the consequences of previous cancer treatments. These factors may negatively affect their ability to tolerate major surgery and recover adequately afterwards. Functional capacity has been identified as an important indicator of physiological reserve and has been associated with postoperative outcomes in surgical oncology populations.
Prehabilitation aims to optimize patients before surgery by improving their physical condition and nutritional status during the period between diagnosis and surgery. This interval represents a potential window of opportunity to enhance a patient's resilience to surgical stress. Previous studies have shown that multimodal prehabilitation programs combining exercise training, nutritional support, and psychological or respiratory interventions may improve preoperative functional capacity and patient wellbeing. However, evidence remains limited in patients undergoing oncological liver resection, particularly in highly optimized healthcare settings where enhanced recovery pathways and minimally invasive surgical techniques are already routinely implemented.
The INPACT study evaluates a multimodal program consisting of structured exercise training, nutritional support, and breathing exercises initiated before surgery and continued during postoperative rehabilitation. The study aims to determine whether this approach can improve patients' functional capacity before surgery and contribute to improved recovery following liver resection.
In addition to evaluating the direct effects of prehabilitation on functional capacity, the study will provide further insight into nutritional status, patient-reported outcomes, postoperative recovery, healthcare utilization, biological markers of inflammation and recovery, and long-term oncological outcomes. The results may contribute to the development and implementation of evidence-based prehabilitation programs for patients undergoing major oncological surgery.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- Age ≥18 years
- Diagnosed with a primary liver cancer or metastases of the liver.
- Patients who need elective surgery (resection)
- Understanding and able to write Dutch or French
- Able and willing to provide written informed consent
Exclusion Criteria:
- Paralytic or immobilised patients who are not able to perform exercises
- Patients scheduled for an ablation
- Kidney dialyse
- Impossibility to wait for 4/5 weeks for elective surgery
- Underlying medical conditions or orthopedic impairments which in the opinion of the investigator places the patient at an unacceptable risk for participation in the study
- Logistic reasons preventing the patient to participate in the pre- and rehabilitation program.
- Unable to perform 6 MWT
- Active cardiac ischemia
Treatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Random assignment
- Masking
- No masking
Multimodal Prehabilitation and Rehabilitation
Participants in the intervention group will follow a structured multimodal prehabilitation and rehabilitation program consisting of physical exercise, nutritional support with protein supplementation, and daily breathing exercises. The prehabilitation program starts approximately four weeks before surgery. After surgery, the program is gradually resumed during the rehabilitation phase according to the patient's recovery and individual capacity.
Behavioral: Multimodal Prehabilitation and Rehabilitation Program
Usual Care
Participants in the control group will receive usual care. Patients are encouraged to remain physically active and receive general advice regarding physical activity and healthy nutrition, but no individualized structured exercise and nutritional program is prescribed or monitored.
Other: Usual Care
Multimodal Prehabilitation and Rehabilitation Program BEHAVIORAL
The multimodal program combines physical exercise, nutritional support, and breathing exercises. During the approximately four-week preoperative period, participants perform two supervised in-hospital exercise sessions per week and three home-based cycling sessions per week. Participants also receive nutritional support including daily protein supplementation and perform daily breathing exercises using a Moonbird device. After surgery, the program is gradually resumed during the rehabilitation phase according to the patient's postoperative recovery and individual capacity.
Usual Care OTHER
Participants receive usual care for patients undergoing oncologic liver surgery. As part of usual care, patients are encouraged to remain physically active and receive general advice regarding physical activity and healthy nutrition. No individualized structured prehabilitation and rehabilitation program is prescribed or monitored.
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Functional capacity measured by the 6-Minute Walk Test (6MWT)
Time frame: 4 weeks after baseline, prior to surgery
Functional capacity will be assessed using the 6-Minute Walk Test (6MWT). The distance walked during 6 minutes will be recorded in meters. The 6MWT distance at the preoperative assessment will be compared between the multimodal prehabilitation group and the usual care group.
Secondary measures
Change in functional capacity measured by the 6-Minute Walk Test (6MWT)
Time frame: From baseline to 4 weeks after baseline and 6 weeks after surgery
Change in distance walked during the 6-Minute Walk Test (6MWT), expressed in meters, will be assessed and compared between the intervention and usual care groups.
Cardiorespiratory fitness measured by VO2max
Time frame: Baseline, 4 weeks after baseline, and 6 weeks after surgery
Cardiorespiratory fitness will be assessed using cardiopulmonary exercise testing (CPET). Maximum oxygen uptake (VO2max) will be compared between the intervention and usual care groups.
Handgrip strength
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Upper-body muscle strength will be assessed using a handgrip strength test and expressed in kilograms. Results will be compared between groups over time.
Lower-extremity muscle strength measured by Biodex
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Lower-extremity muscle strength will be assessed using Biodex dynamometry and compared between the intervention and usual care groups over time.
Single-leg calf raise performance
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Lower-extremity muscle performance will be assessed using the single-leg calf raise test and compared between groups over time.
Sit-to-stand performance
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Functional lower-extremity performance will be assessed using the Sit-to-Stand Test. Participants are instructed to stand up and sit down 10 times as quickly as possible from a chair without using their hands. The outcome measure is the time required to complete 10 repetitions, expressed in seconds. Scores range from 0 seconds to no predefined maximum value. Lower completion times indicate better lower-extremity functional performance, whereas higher completion times indicate worse functional performance.
Health-related quality of life measured by EORTC QLQ-C30
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores are linearly transformed to a 0-100 scale according to the EORTC scoring manual. For the Global Health Status/Quality of Life scale and functional scales, higher scores indicate better quality of life and functioning. For symptom scales and single-item symptom measures, higher scores indicate greater symptom burden and worse quality of life.
Health-related quality of life measured by EQ-5D
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Health-related quality of life and general health status will be assessed using the EuroQol 5-Dimension Questionnaire (EQ-5D). The EQ-5D descriptive system generates an index score ranging from less than 0 (health states considered worse than death) to 1.0 (perfect health), with higher scores indicating better health-related quality of life. The EQ-5D also includes a Visual Analogue Scale (EQ VAS), ranging from 0 to 100, where higher scores indicate better perceived health status.
Postoperative complications measured by the Comprehensive Complication Index (CCI)
Time frame: within 90 days after surgery
Postoperative morbidity will be assessed using the Comprehensive Complication Index (CCI), which summarizes all postoperative complications weighted according to their severity. The CCI score ranges from 0 to 100, where 0 indicates no postoperative complications and 100 indicates death. Higher scores indicate a greater overall burden of postoperative complications and therefore a worse postoperative outcome.
Length of hospital stay
Time frame: From the date of surgery until hospital discharge, assessed up to 90 days after surgery
Length of postoperative hospital stay will be recorded as the number of days from the date of surgery until discharge from the hospital and compared between the intervention and usual care groups.
Nutritional status measured by PG-SGA SF
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Nutritional status will be assessed using the Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF). The total PG-SGA SF score ranges from 0 to 36, with higher scores indicating a greater risk of malnutrition and a worse nutritional status. Lower scores indicate a better nutritional status.
Compliance with nutritional supplementation
Time frame: From baseline until 6 weeks after surgery
Compliance with the prescribed nutritional supplementation will be assessed using the patient diary in participants allocated to the intervention group.
Safety assessed by adverse events and serious adverse events
Time frame: From baseline until 6 weeks after surgery
Safety will be assessed by recording the total number of adverse events (AEs) and serious adverse events (SAEs), as well as the proportion of participants experiencing an AE or SAE.
Compliance with the exercise program
Time frame: Throughout the prehabilitation and rehabilitation program, up to 6 weeks after surgery
Adherence to the exercise program will be assessed using the patient exercise diary and expressed as the percentage of prescribed exercise sessions completed. Perceived exertion during training will be assessed using the Borg Rating of Perceived Exertion Scale. The Borg Rating of Perceived Exertion Scale ranges from 6 to 20, with higher scores indicating greater perceived exercise intensity and exertion.
Three-year disease-free survival
Time frame: 3 years after surgery
Disease-free survival is defined as the time from surgery to the first occurrence of disease recurrence. Participants without recurrence will be censored at the time of last follow-up.
Three-year overall survival
Time frame: 3 years after surgery
Overall survival is defined as the time from surgery to death. Participants who are alive will be censored at the time of last follow-up.
Other measures
Health-economic impact of the multimodal program (sing EQ-5D utility scores and Quality-Adjusted Life Years (QALYs)
Time frame: Through study completion, up to 6 weeks after surgery
An exploratory health-economic analysis will be performed using EQ-5D utility scores to estimate Quality-Adjusted Life Years (QALYs). The health-economic impact of the multimodal prehabilitation and rehabilitation program will be evaluated by comparing QALYs and healthcare resource utilization between the intervention and usual care groups.
Patient perceptions of breathing exercises
Time frame: At or after 6 weeks after surgery
Participants' perceptions and experiences regarding the breathing exercises using the Moonbird device will be explored through semi-structured interviews. Responses will undergo qualitative thematic analysis. This is a qualitative outcome measure and no numerical score will be calculated.
C-Reactive Protein (CRP)
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Serum C-reactive protein (CRP) concentration (mg/L) will be measured and compared between groups. Higher values indicate a greater systemic inflammatory response.
White Blood Cell Count (WBC)
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
White blood cell count (WBC) (×10\^9/L) be measured and compared between groups. Higher values indicate a greater inflammatory response.
Interleukin-6 (IL-6)
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Plasma interleukin-6 (IL-6) (pg/mL) will be measured and compared between groups. Higher values indicate a greater inflammatory response.
Interleukin-8 (IL-8)
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Plasma interleukin-8 (IL-8) concentration (pg/mL) will be measured and compared between groups.
Interleukin-10 (IL-10)
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Plasma interleukin-10 (IL-10) concentration (pg/mL) will be measured and compared between groups.
Tumor Necrosis Factor Alpha (TNF-α)
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Tumor Necrosis Factor Alpha (TNF-α) concentration (pg/mL) will be measured and compared between groups.
Troponin
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Serum troponin concentration (ng/L) will be measured and compared between groups.
Ferritin
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Serum ferritin concentration (µg/L) will be measured and compared between groups.
Albumin
Time frame: Baseline, 4 weeks after baseline, 2 weeks after surgery, and 6 weeks after surgery
Serum albumin concentration (g/L) will be measured and compared between groups. Lower values may indicate impaired nutritional status.
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
AZ GroeningeKortrijk, BelgiumStatus unknown
Study team and timeline
- Lead sponsor
- General Hospital Groeninge
- Study start
- Nov 1, 2026 Estimated
- Primary completion
- Apr 1, 2028 Estimated
- Study completion
- Nov 1, 2030 Estimated
- First posted
- Nov 10, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
INPACT: Implementation of Nutritional Support and Physical Activity During Cancer Treatment
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 11, 2026 · Last registry update: Nov 10, 2026
